Press Releases

Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering simultaneously presented today at the American Society of Clinical Oncology annual meeting and published online in the New England Journal of Medicine.

An international collaboration of researchers is advancing precision medicine for men with advanced prostate cancer.

Memorial Sloan Kettering Cancer Center announced that it has received the largest gift in its history, a commitment of $150 million from long-time MSK board member David H. Koch. This unprecedented contribution will transform cancer care with a state-of-the-art outpatient medical facility to be known as The David H. Koch Center for Cancer Care. The new center will provide the most advanced cancer treatments in a dynamic space designed with the needs of patients firmly in mind.

Memorial Sloan Kettering Cancer Center introduced a new, consumer-friendly web presence for www.mskcc.org (Memorial Sloan Kettering Cancer Center) and www.sloankettering.edu (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center), featuring an innovative platform and on-demand navigation for patients, caregivers, researchers, healthcare professionals, and graduate students, among other core audiences.

Two encouraging Memorial Sloan Kettering Cancer Center (MSK) studies were featured in this year’s American Association for Cancer Research (AACR) Annual Meeting press program.

Positive results from a clinical trial published in <em>The New England Journal of Medicine</em> show that the combination of the immunotherapy drugs ipilimumab (Yervoy^™) and nivolumab (Opdivo^™), produced significantly better outcomes than ipilimumab alone in patients with advanced melanoma. A second piece in the same issue from MSK details a dramatic response occurring after a single dose of the combination therapy.

Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.

The quantity of tests and treatments a cancer patient undergoes could depend largely on where he or she receives care, according to an analysis by researchers at Memorial Sloan Kettering (MSK).

In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health is funding a research collaboration among six institutions in close alliance. The total funding, provided by the National Institute of Allergy and Infectious Diseases, could be up to $45.7 million over seven years.